504 related articles for article (PubMed ID: 14662709)
1. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease.
Fichtlscherer S; Dimmeler S; Breuer S; Busse R; Zeiher AM; Fleming I
Circulation; 2004 Jan; 109(2):178-83. PubMed ID: 14662709
[TBL] [Abstract][Full Text] [Related]
2. Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients.
Taddei S; Versari D; Cipriano A; Ghiadoni L; Galetta F; Franzoni F; Magagna A; Virdis A; Salvetti A
J Am Coll Cardiol; 2006 Aug; 48(3):508-15. PubMed ID: 16875977
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide- and EDHF-mediated arteriolar tone in uremia is unaffected by selective inhibition of vascular cytochrome P450 2C9.
Passauer J; Pistrosch F; Lässig G; Herbrig K; Büssemaker E; Gross P; Fleming I
Kidney Int; 2005 May; 67(5):1907-12. PubMed ID: 15840038
[TBL] [Abstract][Full Text] [Related]
4. Baseline blood flow and bradykinin-induced vasodilator responses in the human forearm are insensitive to the cytochrome P450 2C9 (CYP2C9) inhibitor sulphaphenazole.
Passauer J; Büssemaker E; Lässig G; Pistrosch F; Fauler J; Gross P; Fleming I
Clin Sci (Lond); 2003 Oct; 105(4):513-8. PubMed ID: 12826020
[TBL] [Abstract][Full Text] [Related]
5. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects.
Heitzer T; Rudolph V; Schwedhelm E; Karstens M; Sydow K; Ortak M; Tschentscher P; Meinertz T; Böger R; Baldus S
Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1648-52. PubMed ID: 16675725
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P-450 2C9 signaling does not contribute to age-associated vascular endothelial dysfunction in humans.
Donato AJ; Eskurza I; Jablonski KL; Gano LB; Pierce GL; Seals DR
J Appl Physiol (1985); 2008 Oct; 105(4):1359-63. PubMed ID: 18669935
[TBL] [Abstract][Full Text] [Related]
7. Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients.
Giannarelli C; Virdis A; De Negri F; Magagna A; Duranti E; Salvetti A; Taddei S
Circulation; 2009 Mar; 119(12):1625-33. PubMed ID: 19289643
[TBL] [Abstract][Full Text] [Related]
8. Repetition of ischemic preconditioning augments endothelium-dependent vasodilation in humans: role of endothelium-derived nitric oxide and endothelial progenitor cells.
Kimura M; Ueda K; Goto C; Jitsuiki D; Nishioka K; Umemura T; Noma K; Yoshizumi M; Chayama K; Higashi Y
Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1403-10. PubMed ID: 17446439
[TBL] [Abstract][Full Text] [Related]
9. The role of nitric oxide- and prostacyclin-independent vasodilatation in the human cutaneous microcirculation: effect of cytochrome P450 2C9 inhibition.
Lenasi H
Clin Physiol Funct Imaging; 2009 Jul; 29(4):263-70. PubMed ID: 19291087
[TBL] [Abstract][Full Text] [Related]
10. The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism. Effect of surgical treatment.
Virdis A; Cetani F; Giannarelli C; Banti C; Ghiadoni L; Ambrogini E; Carrara D; Pinchera A; Taddei S; Bernini G; Marcocci C
J Clin Endocrinol Metab; 2010 Feb; 95(2):920-7. PubMed ID: 20022989
[TBL] [Abstract][Full Text] [Related]
11. Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide.
Passauer J; Pistrosch F; Büssemaker E; Lässig G; Herbrig K; Gross P
J Am Soc Nephrol; 2005 Apr; 16(4):959-65. PubMed ID: 15728785
[TBL] [Abstract][Full Text] [Related]
12. Basal production of nitric oxide (NO) and non-NO vasodilators in the forearm microcirculation in Type 2 diabetes: associations with blood pressure and HDL cholesterol.
Woodman RJ; Playford DA; Watts GF
Diabetes Res Clin Pract; 2006 Jan; 71(1):59-67. PubMed ID: 16029909
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease.
Fichtlscherer S; Breuer S; Heeschen C; Dimmeler S; Zeiher AM
J Am Coll Cardiol; 2004 Jul; 44(1):44-9. PubMed ID: 15234404
[TBL] [Abstract][Full Text] [Related]
14. Insulin modulation of an endothelial nitric oxide component present in the alpha2- and beta-adrenergic responses in human forearm.
Lembo G; Iaccarino G; Vecchione C; Barbato E; Izzo R; Fontana D; Trimarco B
J Clin Invest; 1997 Oct; 100(8):2007-14. PubMed ID: 9329964
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effect of vitamin E administration on nitric oxide function in subjects with hypercholesterolaemia.
Green D; O'Driscoll G; Rankin JM; Maiorana AJ; Taylor RR
Clin Sci (Lond); 1998 Sep; 95(3):361-7. PubMed ID: 9730857
[TBL] [Abstract][Full Text] [Related]
16. Pycnogenol, French maritime pine bark extract, augments endothelium-dependent vasodilation in humans.
Nishioka K; Hidaka T; Nakamura S; Umemura T; Jitsuiki D; Soga J; Goto C; Chayama K; Yoshizumi M; Higashi Y
Hypertens Res; 2007 Sep; 30(9):775-80. PubMed ID: 18037769
[TBL] [Abstract][Full Text] [Related]
17. Effect of different intensities of exercise on endothelium-dependent vasodilation in humans: role of endothelium-dependent nitric oxide and oxidative stress.
Goto C; Higashi Y; Kimura M; Noma K; Hara K; Nakagawa K; Kawamura M; Chayama K; Yoshizumi M; Nara I
Circulation; 2003 Aug; 108(5):530-5. PubMed ID: 12874192
[TBL] [Abstract][Full Text] [Related]
18. Sulfaphenazole treatment restores endothelium-dependent vasodilation in diabetic mice.
Elmi S; Sallam NA; Rahman MM; Teng X; Hunter AL; Moien-Afshari F; Khazaei M; Granville DJ; Laher I
Vascul Pharmacol; 2008 Jan; 48(1):1-8. PubMed ID: 17974492
[TBL] [Abstract][Full Text] [Related]
19. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.
Tack CJ; Ong MK; Lutterman JA; Smits P
Diabetologia; 1998 May; 41(5):569-76. PubMed ID: 9628275
[TBL] [Abstract][Full Text] [Related]
20. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients.
John S; Schneider MP; Delles C; Jacobi J; Schmieder RE
Am Heart J; 2005 Mar; 149(3):473. PubMed ID: 15864218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
